ArticleMedComm2025

Artificial Intelligence-Based Multimodal Prediction of Postoperative Adjuvant Immunotherapy Benefit in Urothelial Carcinoma: Results From the Phase III, Multicenter, Randomized, IMvigor010 Trial.

Xiatong Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.